Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29519753 | 0.74 | CYP11B2 (0.40) | FFAR1ARCYP11B1CYP11B2ADORA2A | |
| SCHEMBL193441 | 0.74 | CYP11B2 (0.40) | FFAR1ARCYP11B1CYP11B2ADORA2A | |
| SCHEMBL29815753 | 0.73 | CYP11B1 (0.43) | CDC7FFAR1ARCYP11B1CYP11B2 | |
| SCHEMBL194590 | 0.73 | CYP11B1 (0.43) | CDC7FFAR1ARCYP11B1CYP11B2 | |
| SCHEMBL193697 | 0.71 | FFAR1 (0.33) | FFAR1KAT6ANPC1 | |
| SCHEMBL29816005 | 0.69 | FFAR1 (0.40) | CDC7FFAR1ARCYP11B1CYP11B2 | |
| SCHEMBL193578 | 0.69 | FFAR1 (0.40) | CDC7FFAR1ARCYP11B1CYP11B2 | |
| SCHEMBL15986159 | 0.69 | NPC1 (0.34) | CDC7FFAR1KAT6ACYP11B1CYP11B2 | |
| SCHEMBL9404648 | 0.66 | CA1 (0.44) | KAT6A | |
| SCHEMBL194852 | 0.65 | TSHR (0.48) | CDC7AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | TAKEDA PHARMACEUTICALS CO (JP) | 2019-05-02 | — | — | US | disclosed |
| US-10173977-B2 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-01-08 | — | — | US | disclosed |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CDC7 3684/4885FFAR1 4024/4885PARP1 847/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | CDC7 803/4885FFAR1 2063/4885PARP1 4307/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CDC7 3684/4885FFAR1 4024/4885PARP1 847/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | CDC7 3684/4885FFAR1 4024/4885PARP1 847/4885 |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CDC7 3684/4885FFAR1 4024/4885PARP1 847/4885 |
| US-20190127324-A1 | 5-ARYL-1H-PYRROLE-3-CARBONITRILE AND A PHARMACEUTICAL PRODUCT USING THE SAME | CYP3A5, CYP3A4, CBR3 | CDC7 3981/4885FFAR1 3905/4885PARP1 964/4885 |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | CDC7 3684/4885FFAR1 4024/4885PARP1 847/4885 |
| US-10173977-B2 | 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same | CYP3A5, CYP3A4, CBR3 | CDC7 3981/4885FFAR1 3905/4885PARP1 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.